Gujarat Magazine

Interstitial Lung Disease Market to Rise During the Forecast Period | Puretech, Roche, Atyr Pharma, Oncoarendi, Daewoong Pharma, and others

 Breaking News
  • No posts were found

Interstitial Lung Disease Market to Rise During the Forecast Period | Puretech, Roche, Atyr Pharma, Oncoarendi, Daewoong Pharma, and others

June 19
08:16 2024
Interstitial Lung Disease Market to Rise During the Forecast Period | Puretech, Roche, Atyr Pharma, Oncoarendi, Daewoong Pharma, and others
Interstitial Lung Disease Market
According to DelveInsight, the Interstitial Lung Disease therapeutics market is expected to experience significant growth in the coming years due to the introduction of new therapies and the increasing incidence of Interstitial Lung Disease.

Key players, such as Roche, OncoArendi Pharmaceuticals, aTyr Pharma, Galapagos, and others, are involved in the development of therapies for the treatment of interstitial lung disease (ILD) patients. The companies are mainly working on the development of novel therapies to mimic the natural immune system and cell-based therapies for the management of Interstitial Lung Disease. The major therapies are Pirfenidone, ATYR1923, Abatacept, OATD-01, and others.

DelveInsight’s “Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Interstitial Lung Disease market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Interstitial Lung Disease market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Recent breakthroughs in the interstitial lung disease market:

  • In December 2022, the FDA approved several antibody-drug conjugates (ADCs) for various conditions, including lung diseases. Some of these ADCs include gemtuzumab ozogamicin, inotuzumab ozogamicin, and trastuzumab deruxtecan

  • In March 2020, the U.S. Food and Drug Administration (FDA) approved Ofev (nintedanib) oral capsules for the treatment of patients with chronic fibrosing interstitial lung diseases (ILD) with a progressive phenotype1. This approval marked a significant milestone as it was the first FDA-approved treatment for this group of fibrosing lung diseases that worsen over time.

Interstitial Lung Disease Overview

Interstitial Lung Disease (ILD) refers to a group of lung disorders characterized by progressive scarring (fibrosis) of the lung tissue. This scarring affects the interstitium, which is the tissue and space around the air sacs of the lungs.

Interstitial Lung Disease Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Interstitial Lung Disease market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Interstitial Lung Disease market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Interstitial Lung Disease Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Interstitial Lung Disease Epidemiology, Segmented as –

  • Total Incidence of Interstitial Lung Disease in 7MM (2019–2032)

  • Gender-specific cases of Interstitial Lung Disease (2019–2032) [Male; Female]

  • Subtype-specific cases of Interstitial Lung Disease (2019–2032) [Unknown etiology, exogenous etiology, and variable etiology]

  • Diagnosed and Treatable cases of Interstitial Lung Disease (2019–2032)

Interstitial Lung Disease Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Interstitial Lung Disease market or expected to be launched during the study period. The analysis covers the Interstitial Lung Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Interstitial Lung Disease pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Interstitial Lung Disease Market Will Evolve and Grow by 2032 @

Interstitial Lung Disease Therapeutics Analysis

Among all the pharma players, Pfizer is leading the interstitial lung disease therapeutics market.

Leading Companies in the Interstitial Lung Disease Therapeutics Market Include:

  • Roche

  • aTyr Pharma

  • Boehringer Ingelheim

  • FibroGen

  • LTT Bio-Pharma

  • Bristol-Myers Squibb

  • Prometheus Biosciences

  • HEC Pharm

  • Bayer

  • Insmed

  • Avalyn Pharma

  • PureTech Health

  • Novartis

  • Horizon

Interstitial Lung Disease Emerging and Marketed Drugs Profile:

  • DWN12088: Daewoong Pharmaceutical 

  • LYT-100: PureTech

  • BMS-986278: Bristol-Myers Squibb

  • Pirfenidone: Roche

  • ATYR1923: aTyr Pharma

  • OATD-01: OncoArendi Therapeutics

Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

Table of contents:

1. Key Insights

2. Executive Summary 

3. Interstitial Lung Disease Competitive Intelligence Analysis

4. Interstitial Lung Disease Market Overview at a Glance

5. Interstitial Lung Disease Disease Background and Overview

6. Interstitial Lung Disease Patient Journey

7. Interstitial Lung Disease Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Interstitial Lung Disease Treatment Algorithm, Current Treatment, and Medical Practices

9. Interstitial Lung Disease Unmet Needs

10. Key Endpoints of Interstitial Lung Disease Treatment

11. Interstitial Lung Disease Marketed Products

12. Interstitial Lung Disease Emerging Drugs and Latest Therapeutic Advances

13. Interstitial Lung Disease Seven Major Market Analysis

14. Attribute Analysis

15. Interstitial Lung Disease Market Outlook (In US, EU5, and Japan)

16. Interstitial Lung Disease Access and Reimbursement Overview

17. KOL Views on the Interstitial Lung Disease Market

18. Interstitial Lung Disease Market Drivers

19. Interstitial Lung Disease Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States